Company: TELO
Filing Date: 2025-11-20
Form Type: 8-K
Source: 0001493152-25-024450
Chunk: 1

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: 8-K
Item: Item 8.01
Chunk 1
---
 implicated in leukemia biology.

Interpretation

Taken
together, Telomir-1’s observed activity in HL60 leukemia cells, along with previously reported effects involving intracellular
iron handling and epigenetic regulation, contribute to a scientific basis for Telomir’s ongoing oncology research.

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                         TELOMIR                                       
  Dated:                 By:                        /s/                
                         Name:                      Erez               
                         Title:                     Chief